2.72
-0.02(-0.73%)
Currency In USD
Address
570 South Preston Street
Louisville, KY 40202
United States of America
Phone
502 398 9250
Website
Sector
Healthcare
Industry
Biotechnology
Employees
84
First IPO Date
May 07, 2021
Name | Title | Pay | Year Born |
Ms. Mary Kay Fenton | Interim Chief Executive Officer, Pres, Chief Financial Officer & Treasurer | 598,983 | 1964 |
Mr. Scott Requadt J.D., L.L.B., M.B.A., MBA | Pres, Chief Executive Officer, Sec. & Director | 783,410 | 1968 |
Dr. Suzanne T. Ildstad M.D. | Founder, Member of Scientific Advisory Board, Senior Scientific Advisor & Director | 318,303 | 1953 |
Ms. Nancy Krieger M.D. | Chief Medical Officer | 591,310 | 1967 |
Mr. Michael Zdanowski | Chief Technology Officer | 0 | 1967 |
Mr. Colby Suire Ph.D. | Head of R&D | 0 | N/A |
Ms. Farah Natoli | Head of Portfolio & Program Management | 0 | N/A |
Ms. Courtney Wells | Senior Vice President of Clinical Operations | 0 | N/A |
Mr. Andrew Clyde Farnsworth | Chief HR Officer | 0 | 1959 |
Mr. Eric Gornstein | Senior Vice President of Strategy | 0 | N/A |
Mr. Devin Blass | Vice President of Technical Operations & Site Head | 0 | N/A |
Ms. Suzanne Tollerud | Vice President of Corporation Devel. | 0 | N/A |
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.